Carbon Credits and Decarbonization for Pharma Companies in India: Scope 3, PSCI Audits and Net Zero in 2026

India makes around a fifth of the world's generic medicines and a large share of its vaccines. That scale is becoming a climate obligation as much as a commercial advantage: the buyers who depend on Indian pharma — global innovator companies, European health systems and the NHS — are converting their own net-zero pledges into supplier requirements with hard dates attached. In 2026, those dates are suddenly close.

This guide maps where pharmaceutical emissions actually come from, the compliance and buyer programmes that now apply, a practical decarbonization roadmap for Indian plants, and where verified carbon credits legitimately fit once reductions are underway.

Why 2026 Is the Inflection Year for Pharma Decarbonization

Three forces converged on the industry this year. First, the NHS — one of the largest single buyers of Indian generics — has confirmed its April 2027 milestone: every supplier, regardless of contract size, must publish a Carbon Reduction Plan and a full organisational emissions footprint, with an enhanced standard for contracts worth £5 million a year or more. Product-level carbon data is expected to become the norm from 2028, and from 2030 only suppliers demonstrating real progress will qualify for NHS contracts.

Second, the Pharmaceutical Supply Chain Initiative (PSCI) refreshed its Principles for Responsible Supply Chain Management in 2026, and member audits of Indian API and formulation sites increasingly probe energy and emissions data alongside quality and safety. Alongside the NHS, innovator majors with validated science-based targets — the customers of Indian CDMOs and API exporters — are cascading supplier-engagement commitments down the chain, which is why RFQs increasingly arrive with emissions questionnaires stapled on.

Third, domestic disclosure now has teeth: SEBI's BRSR Core assurance regime is expanding across the top listed companies, pulling pharma majors' emissions data into assured, comparable territory.

Where Pharma Emissions Actually Come From

A pharmaceutical footprint splits very unevenly across the three GHG Protocol scopes. If you are new to the framework, start with our explainer on Scope 1, 2 and 3 emissions for Indian companies. For pharma specifically, the pattern looks like this:

• Scope 1 — direct: steam boilers running on coal, furnace oil or gas, solvent handling and incineration, effluent treatment and captive power. Solvent-heavy API synthesis makes this larger for bulk-drug makers than for formulators.

• Scope 2 — purchased power: cleanrooms are the culprit. HVAC, high air-change rates and filtration routinely account for 50–70% of a sterile site's electricity load.

• Scope 3 — value chain: typically 70–90% of the total. Purchased APIs, intermediates, solvents, excipients and packaging dominate, followed by cold-chain and air-freight logistics and, for respiratory portfolios, patient use of propellant-based inhalers.

Disclosed numbers bear this out. Cipla's reporting shows Scope 3 categories such as purchased goods and use of sold products dwarfing its direct emissions, and the same shape appears across Sun Pharma's and Dr. Reddy's disclosures.

For most Indian pharmaceutical companies, more than 80% of the carbon footprint sits in Scope 3 — decarbonization is a chemistry and procurement problem long before it is an energy problem.

The Compliance and Buyer Landscape: BRSR Core, CCTS, NHS and SBTi

Domestically, listed pharma companies report under BRSR, with BRSR Core's reasonable-assurance requirements tightening year on year. Pharma is notably not an obligated sector under India's Carbon Credit Trading Scheme (CCTS) — but its suppliers of chlor-alkali products and petrochemical-derived solvents are, which means compliance carbon costs will gradually flow into input prices even for companies with no direct CCTS obligation.

Internationally, the SBTi Corporate Net-Zero Standard V2 is reshaping how climate targets get set and validated. Indian leaders have already moved: Dr. Reddy's has committed to net zero by 2045, Sun Pharma targets a 35% cut in Scope 1 and 2 emissions by 2030 against a 2020 baseline, and Cipla has pursued carbon-neutral India manufacturing operations. For everyone else, these peers set the reference point that global buyers will use when they score your questionnaire.

A Practical Decarbonization Roadmap for Indian Pharma

The sequence below reflects what works at Indian sites, ordered roughly by payback:

1. Measure first. Build a site-wise GHG inventory aligned to the GHG Protocol and ISO 14064 — you cannot manage cleanroom loads or supplier emissions you have not quantified.

2. Optimise cleanroom energy. Air-change-rate reviews, HVAC setbacks in unoccupied hours, heat recovery and chiller upgrades typically cut 15–30% of site electricity with modest capex.

3. Green the power supply. Open-access solar and wind, rooftop PV and green tariffs can decarbonize most of Scope 2 in many Indian states, while biomass briquettes can replace coal in steam boilers.

4. Apply green chemistry. Process-mass-intensity reduction, solvent recovery and continuous manufacturing shrink both Scope 1 and upstream Scope 3.

5. Engage suppliers. Extend PSCI-style assessments to API and intermediate vendors and start collecting primary emissions data ahead of product-carbon-footprint requests.

6. Price carbon internally. An internal carbon price prepares capex decisions for a world of border carbon costs and CCTS pass-through.

Where Carbon Credits Fit for Pharma Companies

Credits come after reductions, not instead of them — but they have three legitimate roles in pharma: neutralising residual emissions on the path to net zero, supporting carbon-neutral site or product claims in competitive tenders, and channelling CSR budgets into verifiable climate projects. Nature-based projects, including large-scale plantation programmes, carry community co-benefits many pharma boards value.

Quality is everything: prioritise high-integrity credits with strong additionality and permanence, and treat ICVCM Core Carbon Principles labels as a floor, not a ceiling. Our 2026 buyer's guide to purchasing carbon credits in India covers pricing, registries and due diligence step by step.

Where Csquare Fits

Csquare works with Indian pharmaceutical and life-sciences companies across this whole arc — GHG inventories and BRSR Core-ready disclosure, cleanroom and utility decarbonization roadmaps, renewable procurement advisory, science-based target setting, and sourcing of verified, high-integrity carbon credits and afforestation projects. If NHS deadlines, PSCI audits or buyer questionnaires are landing on your desk, talk to us before the 2027 milestones make the decisions for you.